Immutep Limited (NASDAQ:IMMP – Get Free Report) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.28 and traded as low as $1.91. Immutep shares last traded at $1.95, with a volume of 48,963 shares changing hands.
Analysts Set New Price Targets
Separately, Robert W. Baird decreased their price objective on Immutep from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, June 27th.
Check Out Our Latest Research Report on IMMP
Immutep Price Performance
Institutional Investors Weigh In On Immutep
Several institutional investors have recently added to or reduced their stakes in IMMP. XTX Topco Ltd purchased a new stake in Immutep during the second quarter worth approximately $26,000. BNP Paribas Financial Markets lifted its stake in Immutep by 15.4% during the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock worth $82,000 after purchasing an additional 4,700 shares during the last quarter. XY Capital Ltd purchased a new stake in Immutep during the second quarter worth approximately $105,000. Virtu Financial LLC lifted its stake in Immutep by 269.4% during the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 32,864 shares during the last quarter. Finally, Oracle Investment Management Inc. lifted its stake in Immutep by 9.4% during the first quarter. Oracle Investment Management Inc. now owns 564,879 shares of the biotechnology company’s stock worth $1,316,000 after purchasing an additional 48,449 shares during the last quarter. Hedge funds and other institutional investors own 2.32% of the company’s stock.
Immutep Company Profile
Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.
Recommended Stories
- Five stocks we like better than Immutep
- How to Use High Beta Stocks to Maximize Your Investing Profits
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What Are Dividend Challengers?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Canadian Penny Stocks: Can They Make You Rich?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.